Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs.

[1]  T. Spector,et al.  Glucuronidation of 3'-azido-3'-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. , 1991, Biochemical pharmacology.

[2]  A. Pesce,et al.  Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. , 1991, Transplantation.

[3]  N. White,et al.  Clinical Pharmacokinetics of Mefloquine , 1990, Clinical pharmacokinetics.

[4]  A. Björkman,et al.  Comparison of the activity in vitro of mefloquine and two metabolites against Plasmodium falciparum. , 1990, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[5]  D. Back,et al.  Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. , 1989, British journal of clinical pharmacology.

[6]  J. Bauchet,et al.  Divided-dose kinetics of mefloquine in man. , 1989, British journal of clinical pharmacology.

[7]  D. Back,et al.  In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. , 1988, British journal of clinical pharmacology.

[8]  L. Shipley,et al.  Disposition of the antimalarial, mefloquine, in the isolated perfused rat liver. , 1988, Biochemical pharmacology.

[9]  N. Sonino.  The use of ketoconazole as an inhibitor of steroid production. , 1987, The New England journal of medicine.

[10]  B. K. Park,et al.  The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. , 1987, British journal of clinical pharmacology.

[11]  G. Farrell,et al.  Effects of primaquine on hepatic microsomal haemoproteins and drug oxidation. , 1986, Toxicology.

[12]  I. Cockburn.  Cyclosporine A: a clinical evaluation of drug interactions. , 1986, Transplantation proceedings.

[13]  A. Breckenridge,et al.  The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism. , 1985, British journal of clinical pharmacology.

[14]  H. Webster,et al.  Cloning and characterization of mefloquine-resistant Plasmodium falciparum from Thailand. , 1985, The American journal of tropical medicine and hygiene.

[15]  N. White.  Clinical Pharmacokinetics of Antimalarial Drugs , 1985, Clinical pharmacokinetics.

[16]  D. Back,et al.  Inhibition of tolbutamide metabolism by substituted imidazole drugs in vivo: evidence for a structure‐activity relationship , 1985, British journal of pharmacology.

[17]  K. Speeg,et al.  The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[18]  M. Brown,et al.  Effect of ketoconazole on hepatic oxidative drug metabolism , 1985, Clinical pharmacology and therapeutics.

[19]  D. Back,et al.  Effect of mefloquine on hepatic drug metabolism in the rat: comparative study with primaquine. , 1985, Biochemical pharmacology.

[20]  A. Breckenridge,et al.  The effects of primaquine stereoisomers and metabolites on drug metabolism in the isolated perfused rat liver and in vitro rat liver microsomes. , 1985, Biochemical pharmacology.

[21]  M. Murray.  In vitro effects of quinoline derivatives on cytochrome P-450 and aminopyrine N-demethylase activity in rat hepatic microsomes. , 1984, Biochemical pharmacology.

[22]  B. K. Park,et al.  Effect of chloroquine and primaquine on antipyrine metabolism. , 1983, British journal of clinical pharmacology.

[23]  A. Breckenridge,et al.  Inhibition of drug metabolism by the antimalarial drugs chloroquine and primaquine in the rat. , 1983, Biochemical pharmacology.

[24]  H. Webster,et al.  TYPE II MEFLOQUINE RESISTANCE IN THAILAND , 1982, The Lancet.

[25]  D. E. Schwartz,et al.  Kinetic studies of mefloquine and of one of its metabolites, Ro 21-5104, in the dog and in man. , 1980, Acta tropica.

[26]  N. Molek,et al.  The absorption, distribution, and excretion in mice of the antimalarial mefloquine, erythro-2,8-bis(trifluoromethyl)-alpha-(2-piperidyl)-4-quinolinemethanol hydrochloride. , 1978, Drug metabolism and disposition: the biological fate of chemicals.

[27]  P. Dayton,et al.  Studies of the disposition and metabolism of mefloquine HCl (WR 142,490), a quinolinemethanol antimalarial, in the rat. Limited studies with an analog, WR 30,090. , 1975, Drug metabolism and disposition: the biological fate of chemicals.

[28]  M. Dixon.  The determination of enzyme inhibitor constants. , 1953, The Biochemical journal.

[29]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[30]  N. White,et al.  CLINICAL IMPORTANCE OF ANTIMALARIAL PHARMACOKINETICS , 1988 .

[31]  P. Heizmann,et al.  Single-dose kinetics of mefloquine in Brazilian male subjects. , 1987, Bulletin of the World Health Organization.

[32]  W. Meuldermans,et al.  Interaction of miconazole, ketoconazole and itraconazole with rat-liver microsomes. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.

[33]  D. Back,et al.  Inhibition of ethinyloestradiol and tolbutamide metabolism by quinoline derivatives in vitro. , 1986, Chemico-biological interactions.